As we have reached the end of April, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move | YTD Move |
|---|---|---|
All BPIQ Companies | -7.49% | -39.39% |
CAR-T Companies | -7.17% | -47.81% |
Gene Editing Companies | -7.41% | -50.13% |
XBI | -7.13% | -34.06 |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week of 4/25-4/29
Biggest positive move
$NKTX +140.9% Announced positive data then issued an offering.
Biggest negative move
$ELYM -55.8% Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs - ETX-810 Ph 2a failed and delayed enrollment in ETX-155 ph 2a.
Additional big moves
$PTGX -39.4% Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis
$ARDX +31.8% Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor).
$AVDL -36.0% Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting.
$VERU +25.8% Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases.
$PRTA -14% Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease.
$AVDL +26% Avadel Pharmaceuticals Provides Comment on Recent Trading Activity.
$ERYP -23% Disposition of certain assets and inventory to Catalent.
$SLDB -17.0% Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy source
$FNCH +33.8% Finch Therapeutics Announces Removal of FDA Clinical Hold on CP101 IND source
$ZYME +33.1% Zymeworks Reports Last Patient Enrolled In Pivotal Study Of Zanidatamab In Treatment Of HER2-Expressing Late-Line Biliary Tract Cancer source
$GNCA -24.1% Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives source
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
Keep an eye out for upcoming updates on ASCO
PDUFA target action dates: $SUPN, $HCM, $CHRS, and $AXSM
See our Big Movers post to learn about upcoming Movers throughout April and PDUFAs, after subscribing. Learn more here.